相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dyslipidemia: A Trigger for Coronary Heart Disease in Romanian Patients with Diabetes
Mihnea-Alexandru Gaman et al.
METABOLITES (2020)
New dual peroxisome proliferator activated receptor agonistSaroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
Upendra Kaul et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
Pouya Saeedi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence
Leonardo Pozo et al.
WORLD JOURNAL OF DIABETES (2019)
Management of diabetic dyslipidemia: An update
Ishwarlal Jialal et al.
WORLD JOURNAL OF DIABETES (2019)
PCSK9 inhibitors: A new era of lipid lowering therapy
Rahul Chaudhary et al.
WORLD JOURNAL OF CARDIOLOGY (2017)
A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy
Alka Deshpande et al.
PLOS ONE (2016)
Saroglitazar for the treatment of dyslipidemia in diabetic patients
Shashank R. Joshi
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
Aravind Sosale et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2015)
Saroglitazar, a novel cardiometabolic agent for diabetic dyslipidemia - A Review
Arun Sharma et al.
JOURNAL OF YOUNG PHARMACISTS (2015)
A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)
Rajendrakumar H. Jani et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2014)
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Anders Berg Jorgensen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Safety Profile of Extended-Release Niacin in the AIM-HIGH Trial
Todd J. Anderson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?
Iciar Martin-Timon et al.
WORLD JOURNAL OF DIABETES (2014)
Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPAR alpha Agonist with Moderate PPAR gamma Agonist Activity in Healthy Human Subjects
Rajendra H. Jani et al.
CLINICAL DRUG INVESTIGATION (2013)
Headache disorders: differentiating and managing the common subtypes
Fayyaz Ahmed
BRITISH JOURNAL OF PAIN (2012)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Dyslipidemia and cardiovascular risk: the importance of early prevention
M. Miller
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Statin and fibrate associated myopathy - Study of eight patients
AAS Carvalho et al.
ARQUIVOS DE NEURO-PSIQUIATRIA (2004)
分享论文
